Recent advances in invasive pulmonary aspergillosis

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 3, 2011, Pages 160-166

  Chai, Louis Yi Ann ^a,b   Hsu, Li Yang ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

azoles; cytokines; galactomannan; invasive aspergillosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DECTIN 1; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; PATTERN RECOGNITION RECEPTOR; PLACEBO; POSACONAZOLE; TOLL LIKE RECEPTOR 4; TRIAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ASPERGILLUS; CHEMOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOMEGALOVIRUS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; LUNG ASPERGILLOSIS; LUNG LAVAGE; LUNG MYCOSIS; LUNG NODULE; NONHUMAN; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIFUNGAL AGENTS; BIOLOGICAL MARKERS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MANNANS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; POLYMORPHISM, GENETIC; PYRIMIDINES; TOLL-LIKE RECEPTOR 4; TRIAZOLES;

EID: 79953863295     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328343eb49     Document Type: Review

References (77)

1. Hsu LY, Ng ES, Koh LP. Common and emerging fungal pulmonary infections. Infect Dis Clin North Am 2010; 24:557-577.
2. Sherif R, Segal BH. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med 2010; 16:242-250.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36:1-53.
4. Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin North Am 2006; 20:645-662; vii.
5. McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF Jr. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997; 168:1541-1548.
6. Dagenaise TR, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev 2009; 22:447-465.
7. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-1100. A significant collaborative work highlighting trends in the epidemiology of fungal infections in hematopoietic stem cell transplant recipients over time.
8. Pagano L, Caira M, Candomi A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068-1075. (Pubitemid 44208634)
9. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:1161-1170. (Pubitemid 47580314)
10. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250-260.
11. Caira M, Girmenia C, Fadda RM, et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hematopoietic stem cell transplant: who is at highest risk? Eur J Haematol 2008; 81:242-243.
12. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-1466. (Pubitemid 27225051)
13. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-4366. (Pubitemid 35429674)
14. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139:519-531. (Pubitemid 350043811)
15. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of the Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265-273. This study underlines invasive aspergillosis as the most common invasive fungal infection in hematopoietic stem cell transplant recipients in the United States.
16. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95:644-650. The significant risks of invasive aspergillosis during induction therapy for acute myeloid leukemia are highlighted in this study.
17. Guinea J, Torres-Narbona M, Gijon P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16:870-877.
18. Jorge G, Ursula F, Luigia E, et al. Survey of aspergillosis in nonneutropenic patients in Swiss teaching hospitals. Clin Microbiol Infect 2010 [Epub ahead of print]
19. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45:205-216. (Pubitemid 47044802)
20. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177:27-34.
21. Park SJ, Mehrad B. Innate immunity to Aspergillus species. Clin Microbiol Rev 2009; 22:535-551. A comprehensive review on the interaction between the host immune system and Aspergillus spp.
22. Chai LY, Netea MG, Vonk AG, Kullberg BJ. Fungal strategies for overcoming host innate immune response. Med Mycol 2009; 47:227-236.
23. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.NEngl JMed2008;359:1766-1777.
24. Carvalho A, Pasqualotto AC, Pitzurra L, et al. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008; 197:618-621. (Pubitemid 351321541)
25. Carvalho A, Cunha C, Carotti A, et al. Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. Exp Hematol 2009; 37:1022-1029.
26. Levitz SM, Shoham S, Cleary JD. Toll-like receptor 4 polymorphisms and aspergillosis. N Engl J Med 2009; 360:634.
27. Von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 32:691-696.
28. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361:1760-1767.
29. Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphismassociates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116:5394-5402. Dectin-1 polymorphism may be associated with invasive aspergillosis susceptibility in the hematopoietic stem cell transplant recipient cohort reported here.
30. Chai LA, de Boer MG, van der Velden WJ, et al. The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis (in press).
31. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-1427.
32. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2008:CD007394.
33. Hachem RY, Kontoyiannis DP, Chemaly RF, et al. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009; 47:129-133.
34. Cordonnier C, Botterel F, Ben Amor R, et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 2009; 15:81-86.
35. Guo YL, Chen YQ, Wang K, et al. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010; 138:817-824. This meta-analysis reports that bronchoalveolar lavage galactomannan testing is sensitive and specific for the diagnosis of invasive aspergillosis.
36. Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49:1688-1693.
37. Hsu LY, Ding Y, Phua J, et al. Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients. BMC Infect Dis 2010; 10:44.
38. Luong ML, Filion C, Labbe AC, et al. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis 2010; 68:132-139.
39. Pasqualotto AC, Xavier MO, Sanchez LB, et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation 2010; 90:306-311.
40. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
41. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253-259. (Pubitemid 32063503)
42. Millito MA, Kontoyiannis DP, Lewis RE, et al. Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. Med Mycol 2010; 48:817-823.
43. Hachem R, Sumoza D, Hanna H, et al. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) be revised? Cancer 2006; 106:1581-1586.
44. Nucci M, Nouer SA, Grazziutti M, et al. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 2010; 51:1273-1280. This retrospective study assess the utility of the EORTC/MSG radiologic criteria in the diagnosis of invasive aspergillosis.
45. Boutbol F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34:939-943. (Pubitemid 34229762)
46. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115:355-362.
47. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412-1422. (Pubitemid 351589942)
48. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48:1255-1260. Serum galactomannan levels may prognosticate outcomes of invasive aspergillosis.
49. Koo S, Bryar JM, Page JH, et al. Diagnostic performance of the (1→3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49:1650-1659.
50. Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6:67-78. (Pubitemid 350286221)
51. Chai LA, Netea MG, Teerenstra S, et al. Early proinflammatory cytokines and C-reactive protein trends as predictors of outcome in invasive aspergillosis. J Infect Dis 2010; 202:1454-1462.
52. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-359. (Pubitemid 46148777)
53. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401-1408. (Pubitemid 351589940)
54. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57:317-325. (Pubitemid 43160176)
55. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-2061.
56. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-1552.
57. Wingard JR, Carter SL, Walsh TJ, et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). Blood 2010; 116:5111-5118. This recent study found no difference in rates of invasive fungal infections among hematopoietic stem cell transplant recipients who received either fluconazole or voriconazole as prophylaxis.
58. Cordonnier C, Ravira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95:1762-1768. As secondary prophylaxis against invasive fungal infections during hematopoietic stem cell transplantation, voriconazole may be an option as reported in this study.
59. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347. (Pubitemid 46148776)
60. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356:409-411.
61. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415. (Pubitemid 34851833)
62. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-1297. (Pubitemid 46717290)
63. Cornely OA, Maertens J, Bresnik M, et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2010 [Epub ahead of print]
64. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35:359-366. (Pubitemid 34852563)
65. Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64:1274-1281.
66. Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45:1227-1233.
67. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97:135-144. (Pubitemid 24250673)
68. Walsh TJ, Annaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360. (Pubitemid 351265310)
69. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-1571. (Pubitemid 39578526)
70. Hiemenz JW, Raad II, Maertens JA, et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 2010; 29:1387-1394.
71. Maertens J, Egerer G, Shin WS, et al. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry. BMC Infect Dis 2010; 10:182.
72. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107:2888-2897. (Pubitemid 44937044)
73. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292-299. (Pubitemid 36828453)
74. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802. (Pubitemid 39244292)
75. Mihu CN, Kassis C, Ramos ER, et al. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer 2010; 116:5290-5296. Retrospective study, but significant in that no positive benefits of combination therapy with liposomal amphotericin B and echinocandins were found.
76. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12. (Pubitemid 44968977)
77. Raad II, Hanna HA, Boktour M, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008; 22:496-503. (Pubitemid 351395097)